Medicinal products — List of marketing authorisations granted by the EEA EFTA States for the second half of 2011
Date: 2014-10-09
Institutions: Standing Committee of the EFTA States
Subjects: EFTA countries, free movement of goods, market approval, medicinal product








C_2014356EN.01000701.xml










9.10.2014   


EN


Official Journal of the European Union


C 356/7





Medicinal products — List of marketing authorisations granted by the EEA EFTA States for the second half of 2011
2014/C 356/06

Subcommittee I on the free movement of goods


To be noted by the EEA Joint Committee

With reference to EEA Joint Committee Decision No 74/1999 of 28 May 1999, the EEA Joint Committee is invited to note the following lists concerning marketing authorisations for medicinal products for the period 1 July - 31 December 2011, at their meeting on 15 June 2012:







Annex I



List of new marketing authorisations





Annex II



List of renewed marketing authorisations





Annex III



List of extended marketing authorisations





Annex IV



List of withdrawn marketing authorisations





Annex V



List of suspended marketing authorisations






ANNEX I
List of new marketing authorisations
The following marketing authorisations have been granted in the EEA EFTA States during the period 1 July- 31 December 2011:








EU-Number


Product


Country


Date of authorisation




EU/1/09/543/001-002


Cayston (1)



Liechtenstein


31.10.2011




EU/1/10/642/001-004


Ibandronic Acid Teva


Norway


23.8.2011




EU/1/10/649/001-016


Clopidogrel Teva Pharma B.V


Norway


19.7.2011




EU/1/10/649/001-016


Clopidogrel Teva Pharma B.V.


Liechtenstein


31.8.2011




EU/1/10/652/001-003


TOBI Podhaler


Liechtenstein


31.8.2011




EU/1/10/652/001-003


TOBI Podhaler


Norway


17.8.2011




EU/1/10/652/001-003


TOBI Podhaler


Iceland


9.8.2011




EU/1/10/654/001-004


Leflunomide ratiopharm


Norway


25.8.2011




EU/1/10/660/001-002


Potactasol


Norway


24.8.2011




EU/1/10/661/001-002


Fluenz


Norway


23.8.2011




EU/1/11/672/001-006


Xeplion


Liechtenstein


31.10.2011




EU/1/11/683/001-080


Sprimeo HCT


Liechtenstein


31.8.2011




EU/1/11/683/001-080


Sprimeo HCT


Norway


22.8.2011




EU/1/11/683/001-080


Sprimeo HCT


Iceland


10.8.2011




EU/1/11/685/001-005


Ibandronic acid Sandoz


Liechtenstein


31.8.2011




EU/1/11/685/001-005


Ibandronic acid Sandoz


Iceland


18.8.2011




EU/1/11/689/001-002


IOA


Liechtenstein


31.12.2011




EU/1/11/689/001-002


IOA


Norway


6.12.2011




EU/1/11/689/001-002


Ioa


Iceland


25.11.2011




EU/1/11/690/001-002


Zoely


Liechtenstein


31.8.2011




EU/1/11/690/001-002


Zoely


Norway


18.8.2011




EU/1/11/690/001-002


Zoely


Iceland


9.8.2011




EU/1/11/691/001-005


Eliquis


Iceland


8.8.2011




EU/1/11/693/001-016


Rivastigmin Actavis


Norway


19.8.2011




EU/1/11/694/001-002


Nulojix


Liechtenstein


31.8.2011




EU/1/11/694/001-002


Nulojix


Norway


1.8.2011




EU/1/11/694/001-002


Nulojix


Iceland


6.7.2011




EU/1/11/695/001-055


Leganto


Liechtenstein


31.8.2011




EU/1/11/695/001-055


Leganto


Norway


23.8.2011




EU/1/11/695/001-055


Leganto


Iceland


6.7.2011




EU/1/11/696/001-002


Bydureon


Norway


5.7.2011




EU/1/11/696/001-002


Bydureon


Iceland


6.7.2011




EU/1/11/696/001-002


Bydureon


Liechtenstein


31.8.2011




EU/1/11/697/001-012


Temozolomide Sun


Liechtenstein


31.8.2011




EU/1/11/697/001-012


Temozolomide SUN


Norway


22.8.2011




EU/1/11/697/001-012


Temozolomide SUN


Iceland


9.8.2011




EU/1/11/698/001-002


Yervoy


Liechtenstein


31.8.2011




EU/1/11/698/001-002


Yervoy


Norway


18.8.2011




EU/1/11/698/001-002


Yervoy


Iceland


21.7.2011




EU/1/11/699/001-002


Fampyra


Liechtenstein


31.8.2011




EU/1/11/699/001-002


Fampyra


Norway


23.8.2011




EU/1/11/699/001-002


Fampyra


Iceland


9.8.2011




EU/1/11/700/001-002


Benlysta


Liechtenstein


31.8.2011




EU/1/11/700/001-002


Benlysta


Norway


27.7.2011




EU/1/11/700/001-002


Benlysta


Iceland


21.7.2011




EU/1/11/701/001-028


Levetiracetam Teva


Liechtenstein


31.10.2011




EU/1/11/701/001-028


Levetiracetam Teva


Norway


26.9.2011




EU/1/11/701/001-028


Levetiracetam Teva


Iceland


16.9.2011




EU/1/11/702/001-031


Levetiracetam Ratiopharm


Liechtenstein


31.10.2011




EU/1/11/702/001-031


Levetiracetam ratiopharm


Norway


26.9.2011




EU/1/11/702/001-031


Levetiracetam ratiopharm


Iceland


16.9.2011




EU/1/11/703/001-002


Xgeva


Liechtenstein


31.8.2011




EU/1/11/703/001-002


Xgeva


Norway


15.8.2011




EU/1/11/703/001-002


XGEVA


Iceland


21.7.2011




EU/1/11/704/001


Victrelis


Liechtenstein


31.8.2011




EU/1/11/704/001


Victrelis


Norway


16.8.2011




EU/1/11/704/001


Victrelis


Iceland


10.8.2011




EU/1/11/705/001-002


Vibativ


Liechtenstein


31.10.2011




EU/1/11/705/001-002


Vibativ


Norway


19.9.2011




EU/1/11/705/001-002


Vibativ


Iceland


16.9.2011




EU/1/11/706/001-033


Levodopa/Cardidopa/Entacapone Orion


Liechtenstein


31.10.2011




EU/1/11/706/001-033


Levodopa/Carbidopa/Entacapone Orion


Norway


23.9.2011




EU/1/11/706/001-033


Levodopa/Carbidopa/Entacapone Orion


Iceland


14.9.2011




EU/1/11/707/001-011


Trajenta


Liechtenstein


31.10.2011




EU/1/11/707/001-011


Trajenta


Norway


12.9.2011




EU/1/11/707/001-011


Trajenta


Iceland


14.9.2011




EU/1/11/708/001-004


Entacapone Orion


Liechtenstein


31.8.2011




EU/1/11/708/001-004


Entacapone Orion


Norway


22.9.2011




EU/1/11/708/001-004


Entacapone Orion


Iceland


26.8.2011




EU/1/11/709/001-004


Buccolam


Norway


27.9.2011




EU/1/11/709/001-03


Buccolam


Iceland


1.11.2011




EU/1/11/710/001-007


Votubia


Liechtenstein


31.10.2011




EU/1/11/710/001-007


Votubia


Norway


15.9.2011




EU/1/11/710/001-007


Votubia


Iceland


16.9.2011




EU/1/11/711/001-030


Matever


Liechtenstein


31.10.2011




EU/1/11/711/001-030


Matever


Iceland


13.10.2011




EU/1/11/712/001-028


Levetiracetam Accord


Liechtenstein


31.10.2011




EU/1/11/712/001-028


Levetiracetam Accord


Iceland


6.11.2011




EU/1/11/713/001-040


Levetiracetam Actavis


Liechtenstein


31.10.2011




EU/1/11/713/001-040


Levetiracetam Actavis


Iceland


13.10.2011




EU/1/11/714/001


Zytiga


Liechtenstein


31.10.2011




EU/1/11/714/001


Zytiga


Norway


26.9.2011




EU/1/11/714/001


Zytiga 250 mg Tafla


Iceland


19.9.2011




EU/1/11/715/001-002


Plenadren


Liechtenstein


31.12.2011




EU/1/11/715/001-002


Plenadren


Norway


25.11.2011




EU/1/11/716/001-005


Eurartesim


Liechtenstein


31.12.2011




EU/1/11/716/001-005


Eurartesim


Norway


21.12.2011




EU/1/11/716/001-005


Eurartesim


Iceland


10.11.2011




EU/1/11/717/001


Vyndaqel


Liechtenstein


31.12.2011




EU/1/11/717/001


Vyndaqel


Norway


6.12.2011




EU/1/11/717/001


Vyndaqel


Iceland


25.11.2011




EU/1/11/718/001-006


Dexdor


Liechtenstein


31.10.2011




EU/1/11/718/001-006


Dexdor


Norway


11.10.2011




EU/1/11/718/001-006


Dexdor


Iceland


30.9.2011




EU/1/11/719/001-060


Telmisartan Teva Pharma


Norway


18.10.2011




EU/1/11/719/001-060


Telmisartan Teva Pharma


Iceland


6.11.2011




EU/1/11/720/001


Incivo


Liechtenstein


31.10.2011




EU/1/11/720/001


Incivo


Norway


6.10.2011




EU/1/11/720/001


Incivo 375 mg Filmuhúðuð tafla


Iceland


8.10.2011




EU/1/11/728/001-010


Pramipexole Accord


Liechtenstein


31.10.2011




EU/1/11/728/001-010


Pramipexole Accord


Norway


18.10.2011




EU/1/11/728/001-010


Pramipexole Accord


Iceland


10.10.2011




EU/1/11/729/001-006


Onduarp


Liechtenstein


31.12.2011




EU/1/11/729/001-006


Onduarp


Iceland


14.12.2011




EU/1/11/730/001-060


Rasitrio


Norway


7.12.2011




EU/1/11/731/001-012


Komboglyze


Liechtenstein


31.12.2011




EU/1/11/731/001-012


Komboglyze


Norway


15.12.2011




EU/1/11/731/001-012


Komboglyze


Iceland


8.12.2011




EU/1/11/732/001-013


Desloratadine Teva


Liechtenstein


31.12.2011




EU/1/11/732/001-013


Desloratadine Teva


Norway


20.12.2011




EU/1/11/732/001-013


Desloratadine Teva


Iceland


8.12.2011




EU/1/11/733/001-004


Dificlir


Liechtenstein


31.12.2011




EU/1/11/733/001-004


Dificlir


Norway


20.12.2011




EU/1/11/733/001-004


Dificlir


Iceland


14.12.2011




EU/1/11/734/001-011


Edarbi


Liechtenstein


31.12.2011




EU/1/11/734/001-011


Edarbi


Norway


21.12.2011




EU/1/11/734/001-011


Edarbi


Iceland


17.12.2011




EU/1/11/735/001-011


Ipreziv


Liechtenstein


31.12.2011




EU/1/11/735/001-011


Ipreziv


Norway


21.12.2011




EU/1/11/735/001-011


Ipreziv


Iceland


17.12.2011




EU/1/11/736/001


Edurant


Liechtenstein


31.12.2011




EU/1/11/736/001


Edurant


Norway


6.12.2011




EU/1/11/736/001


EDURANT


Iceland


14.12.2011




EU/1/11/737/001-002


Eviplera


Liechtenstein


31.12.2011




EU/1/11/737/001-002


Eviplera


Norway


6.12.2011




EU/1/11/737/001-002


Eviplera


Iceland


14.12.2011




EU/1/11/738/001-003


Levetiracetam Actavis Group


Liechtenstein


31.12.2011




EU/1/11/738/001-003


Levetiracetam Actavis Group


Iceland


14.12.2011




EU/1/11/739/001-008


Dasselta


Liechtenstein


31.12.2011




EU/1/11/739/001-008


Dasselta


Iceland


8.12.2011




EU/1/11/740/001


Ameluz


Liechtenstein


31.12.2011




EU/2/07/078/011-014


Rheumocam


Norway


6.7.2011




EU/2/10/110/001-002


Coxevac


Norway


22.8.2011




EU/2/10/112/001-005


BTVPUR AlSap 1


Norway


22.8.2011




EU/2/10/113/001-005


BTVPUR AlSap 1-8


Norway


23.8.2011




EU/2/11/122/001-003


Bluevac BTV8


Iceland


12.7.2011




EU/2/11/124/001-008


Zuprevo


Norway


6.7.2011




EU/2/11/125/001-008


Certifect


Norway


1.9.2011




EU/2/11/126/001


MS-H-vaksine – Mycoplasma synoviae


Norway


5.7.2011




EU/2/11/127/001


Recuvyra


Norway


6.12.2011




EU/2/11/127/001


RECUVYRA


Iceland


11.11.2011




EU/2/11/128/001-003


Emdocam


Norway


14.9.2011




EU/2/11/128/001-003


Emdocam


Iceland


8.9.2011




EU/2/11/129/001-004


Proteq West Nile


Norway


19.8.2011




EU/2/11/129/001-004


Proteq West Nile


Iceland


12.8.2011




EU/2/11/130/001-003


Zulvac 1 Bovis


Norway


17.8.2011




EU/2/11/130/001-003


Zulvac 1 Bovis


Iceland


18.8.2011




EU/2/11/131/001-006


Zulvac 1 Ovis


Norway


17.8.2011




EU/2/11/131/001-006


Zulvac 1 Ovis


Iceland


12.8.2011




EU/2/11/132/001-004


Nobivac Myxo-RHD


Norway


19.9.2011




EU/2/11/132/001-004


Nobivac Myxo-RHD


Iceland


20.9.2011




EU/2/11/133/001-003


Recocam


Norway


6.10.2011




EU/2/11/133/001-003


Recocam 20 mg/ml


Iceland


23.9.2011




EU/2/11/134/001-014


Inflacam


Iceland


19.12.2011




EU/2/11/135/001-003


Panacur AquaSol


Iceland


19.12.2011






(1)  From the conditional marketing authorisation with a marketing authorisation not subject to specific obligations.



ANNEX II
List of renewed marketing authorisations
The following marketing authorisations have been renewed in the EEA EFTA States during the period 1 July- 31 December 2011:








EU-Number


Product


Country


Date of authorisation




EU/1/01/196/001
EU/1/01/196/003


Cancidas


Norway


20.9.2011




EU/1/01/196/001, 003


Cancidas


Iceland


20.9.2011




EU/1/01/196/001, 003


Cancidas


Liechtenstein


31.10.2011




EU/1/01/200/001-002


Viread


Liechtenstein


31.12.2011




EU/1/06/336/001


Tygacil


Iceland


13.7.2011




EU/1/06/340/001-002


Ganfort


Liechtenstein


31.8.2011




EU/1/06/340/001-002


Ganfort


Norway


1.9.2011




EU/1/06/340/001-002


Ganfort


Iceland


8.7.2011




EU/1/06/342/001


Nexavar


Liechtenstein


31.8.2011




EU/1/06/342/001


Nexavar


Norway


20.9.2011




EU/1/06/342/001


Nexavar


Iceland


9.8.2011




EU/1/06/343/001-007


Baraclude


Norway


6.7.2011




EU/1/06/346/001


Tysabri


Liechtenstein


31.8.2011




EU/1/06/346/001


Tysabri


Norway


19.7.2011




EU/1/06/35/001-003


Livensa


Liechtenstein


31.8.2011




EU/1/06/350/001


Savene


Liechtenstein


31.8.2011




EU/1/06/350/001


Savene


Norway


18.8.2011




EU/1/06/350/001


Savene


Iceland


9.8.2011




EU/1/06/351/001-003


Livensa


Norway


12.8.2011




EU/1/06/351/001-003


Livensa


Iceland


9.8.2011




EU/1/06/352/001-003


Intrinsa


Liechtenstein


31.8.2011




EU/1/06/352/001-003


Intrinsa


Norway


12.8.2011




EU/1/06/352/001-003


Intrinsa


Iceland


10.8.2011




EU/1/06/355/001-003


ATryn


Liechtenstein


31.8.2011




EU/1/06/355/001-003


ATryn


Norway


1.9.2011




EU/1/06/355/001-003


ATryn


Iceland


18.8.2011




EU/1/06/356/001-009


Exjade


Liechtenstein


31.8.2011




EU/1/06/356/001-009


Exjade


Norway


17.8.2011




EU/1/06/356/001-009


Exjade


Iceland


9.8.2011




EU/1/06/357/001-008, 018-021


Gardasil


Iceland


11.8.2011




EU/1/06/357/001-008
EU/1/06/357/018-021


Gardasil


Norway


19.8.2011




EU/1/06/358/001-008, 018-021


Silgard


Iceland


10.8.2011




EU/1/06/358/001-021


Silgard


Liechtenstein


31.8.2011




EU/1/06/358/001-021


Silgard


Norway


12.8.2011




EU/1/06/359/001-004


Suboxone


Liechtenstein


31.10.2011




EU/1/06/359/001-004


Suboxone


Norway


14.10.2011




EU/1/06/359/001-004


Suboxone


Iceland


4.10.2011




EU/1/06/360/001-013


Champix


Norway


3.8.2011




EU/1/06/360/001-013


Champix


Iceland


7.7.2011




EU/1/06/361/001-002


Luminity


Liechtenstein


31.10.2011




EU/1/06/361/001-002


Luminity


Norway


21.9.2011




EU/1/06/361/001-002


Luminity


Iceland


21.9.2011




EU/1/06/362/001-004


Byetta


Liechtenstein


31.10.2011




EU/1/06/362/001-004


Byetta


Norway


6.10.2011




EU/1/06/362/001-004


Byetta


Iceland


8.10.2011




EU/1/06/363/001-015


Sprycel


Liechtenstein


31.10.2011




EU/1/06/363/001-015


Sprycel


Norway


14.10.2011




EU/1/06/363/001-015


Sprycel


Iceland


7.11.2011




EU/1/06/364/001-004
EU/1/06/364/006-008


Adrovance


Norway


23.12.2011




EU/1/06/364/001-004, 006-008


Adrovance


Iceland


7.12.2011




EU/1/06/364/006-008


Adrovance


Liechtenstein


31.12.2011




EU/1/06/365/001-003


Elaprase


Liechtenstein


31.10.2011




EU/1/06/365/001-003


Elaprase


Norway


14.10.2011




EU/1/06/365/001-003


Elaprase


Iceland


6.11.2011




EU/1/06/368/001-015, 020-024, 029-033, 038-042, 047-051, 056-057, 088-102, 113-150, 163-168


Insulin Human Winthrop


Liechtenstein


31.12.2011




EU/1/06/368/001-168


Insulin Human Winthrop


Iceland


6.12.2011




EU/1/06/370/001-039


Exforge


Liechtenstein


31.12.2011




EU/1/06/372/001-039


Copalia


Liechtenstein


31.12.2011




EU/1/06/372/001-039


Copalia


Iceland


7.12.2011




EU/1/06/373/001-039


Imprida


Liechtenstein


31.12.2011




EU/1/07/440/001-006


Tyverb


Iceland


22.8.2011




EU/1/08/468/001


Intelence


Liechtenstein


31.8.2011




EU/1/08/468/001


Intelence


Norway


17.8.2011




EU/1/08/468/001


INTELENCE


Iceland


11.8.2011




EU/1/09/543/001-002


Cayston


Norway


19.9.2011




EU/1/09/543/001-002


Cayston


Iceland


19.9.2011




EU/1/10/628/001-004


Votrient


Norway


21.10.2011




EU/1/96/024/001-005


Crixivan


Liechtenstein


31.8.2011




EU/1/96/024/001-005
EU/1/96/024/010


Crixivan


Norway


18.8.2011




EU/1/96/024/001-010


Crixivan


Iceland


10.8.2011




EU/2/06/059/001


Convenia


Norway


6.7.2011




EU/2/06/060/001-002


Poulvac Flufend H5N3 RG


Iceland


11.8.2011




EU/2/06/061/001-004


Nobilis Influenza H5N2


Norway


14.9.2011




EU/2/06/061/001-004


Nobilis Influenza H5N2


Iceland


8.9.2011




EU/2/06/062/001-005


Cerenia


Norway


18.8.2011




EU/2/06/062/001-005


Cerenia


Iceland


12.8.2011




EU/2/06/064/001-004


ProMeris


Norway


8.12.2011




EU/2/06/064/001-004


ProMeris


Iceland


21.11.2011




EU/2/06/065/001-010


ProMeris Duo


Iceland


4.12.2011




EU/2/06/065/001-010


ProMeris Duo


Norway


8.12.2011




EU/2/06/066/001-012


Prac-Tic


Norway


8.12.2011




EU/2/06/066/001-012


Prac-tic


Iceland


25.11.2011




EU/2/06/069/001


Cortavance


Norway


27.9.2011




EU/2/06/069/001


Cortavance


Iceland


23.9.2011




EU/2/99/016/001-006


Porcilis Pesti


Norway


6.10.2011




EU/2/99/016/001-006


Porcilis Pesti


Iceland


7.10.2011







ANNEX III
List of extended marketing authorisations
The following marketing authorisations have been extended in the EEA EFTA States during the period 1 July- 31 December 2011:








EU-Number


Product


Country


Date of authorisation




EU/1/00/165/008


Ovitrelle


Liechtenstein


31.8.2011




EU/1/00/165/008


Ovitrelle


Norway


6.7.2011




EU/1/01/176/007-009


Zometa


Liechtenstein


31.10.2011




EU/1/01/176/007-009


Zometa


Norway


12.9.2011




EU/1/01/176/007-009


Zometa


Iceland


12.11.2011




EU/1/02/221/011-016


Pegasys


Liechtenstein


31.8.2011




EU/1/03/248/013-023


Levitra


Liechtenstein


31.12.2011




EU/1/03/249/013-015


Vivanza


Liechtenstein


31.12.2011




EU/1/03/260/034-038


Stalevo


Norway


23.9.2011




EU/1/03/260/034-038


Stalevo


Liechtenstein


31.10.2011




EU/1/03/260/034-038


Stalevo


Iceland


13.9.2011




EU/1/03/262/009-010


Emend


Liechtenstein


31.12.2011




EU/1/03/270/004-005


Kentera


Liechtenstein


31.8.2011




EU/1/03/270/004-005


Kentera


Norway


7.9.2011




EU/1/03/270/004-005


Kentera


Iceland


9.9.2011




EU/1/03/271/007-010


Advate


Liechtenstein


31.12.2011




EU/1/05/322/002


Yttriga


Liechtenstein


31.8.2011




EU/1/06/332/010-012


Omnitrope


Norway


25.8.2011




EU/1/06/378/017


Inovelon


Liechtenstein


31.12.2011




EU/1/06/378/017


Inovelon


Norway


20.12.2011




EU/1/07/392/003


Circadin


Liechtenstein


31.10.2011




EU/1/07/401/016


Alli


Liechtenstein


31.8.2011




EU/1/07/422/007-008


Tasigna


Liechtenstein


31.8.2011




EU/1/07/422/009-012


Tasigna


Liechtenstein


31.12.2011




EU/1/08/442/009-013


Pradaxa


Iceland


10.8.2011




EU/1/08/442/009-014


Pradaxa


Liechtenstein


31.8.2011




EU/1/08/442/009-014


Pradaxa


Norway


17.8.2011




EU/1/08/468/002


Intelence


Liechtenstein


31.12.2011




EU/1/08/468/002


Intelence


Norway


15.12.2011




EU/1/08/470/014-015


Vimpat


Iceland


8.12.2011




EU/1/08/472/011-021


Xarelto


Liechtenstein


31.12.2011




EU/1/08/472/011-021


Xarelto


Iceland


20.12.2011




EU/1/09/508/011


Synflorix


Liechtenstein


31.8.2011




EU/1/09/531/010-021


Instanyl


Liechtenstein


31.8.2011




EU/1/09/531/010-021


Instanyl


Norway


1.8.2011




EU/1/09/531/010-021


Instanyl


Iceland


13.7.2011




EU/1/09/564/003


Ilaris


Liechtenstein


31.10.2011




EU/1/09/564/003


Ilaris


Iceland


5.10.2011




EU/1/09/564/003


Ilaris


Norway


27.9.2011




EU/1/09/610/031-060


Telmisartan Teva


Liechtenstein


31.8.2011




EU/1/10/614/003


Menveo


Liechtenstein


31.8.2011




EU/1/10/636/004-007


Daxas


Liechtenstein


31.12.2011




EU/1/10/646/003-006


VPRIV


Liechtenstein


31.8.2011




EU/1/10/647/003-004


Myclausen


Norway


27.9.2011




EU/1/10/647/003-004


Myclausen


Iceland


3.10.2011




EU/1/95/003/011-012


Betaferon


Liechtenstein


31.8.2011




EU/1/97/055/005-009


Viramune


Norway


14.10.2011




EU/1/97/055/005-009


Viramune


Iceland


5.10.2011




EU/1/98/090/021-022


Micardis


Liechtenstein


31.8.2011




EU/1/99/119/019-023


NovoRapid


Liechtenstein


31.8.2011




EU/1/99/126/022


Enbrel


Iceland


13.7.2011




EU/2/08/090/010-018


Loxicom


Norway


15.8.2011




EU/2/08/090/010-026


Loxicom


Iceland


22.7.2011




EU/2/08/090/019-026


Loxicom


Norway


27.9.2011







ANNEX IV
List of withdrawn marketing authorisations
The following marketing authorisations have been withdrawn in the EEA EFTA States during the period 1 July- 31 December 2011:








EU-Number


Product


Country


Date of withdrawal




EU/1/02/225/001-002


Xigris


Liechtenstein


31.12.2011




EU/1/03/259/001-006


Onsenal


Norway


5.8.2011




EU/1/05/313/001-009


Ablavar


Liechtenstein


31.10.2011




EU/1/05/313/001-009


Ablavar


Norway


29.11.2011




EU/1/05/313/001-009


Ablavar


Iceland


6.11.2011




EU/1/08/470/014-015


Vimpat


Iceland


8.12.2011




EU/1/08/478/001


Prepandemic influenza vaccine (H5N1)


Liechtenstein


31.10.2011




EU/1/08/478/001


Prepandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted) GlaxoSmithKline Biologicals


Iceland


6.11.2011




EU/1/09/547/001-007


Clopidogrel Sandoz


Norway


5.8.2011




EU/1/09/547/001-007


Clopidogrel Sandoz


Iceland


23.8.2011




EU/1/10/629/001


Humenza


Norway


5.8.2011




EU/2/06/063/001-003


Yarvitan


Norway


22.9.2011




EU/2/06/063/001-003


Yarvitan


Iceland


26.8.2011




EU/1/06/349/001-010


Avaglim


Norway


18.8.2011







ANNEX V
List of suspended marketing authorisations
The following marketing authorisations have been suspended in the EEA EFTA States during the period 1 July- 31 December 2011:








EU-Number


Product


Country


Date of suspension




EU/1/06/361/001-002


Luminity


Liechtenstein


31.12.2011




EU/2/08/088/001-003


Acticam


Iceland


23.8.2011